Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release
Kevin Dang, Giulia Castello, Starlynn Clarke, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 6, pp. e002488-e002488
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

The present and future of bispecific antibodies for cancer therapy
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 119
Bispecific antibodies in cancer therapy: Target selection and regulatory requirements
Yanze Sun, Xinmiao Yu, Xiao Wang, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 9, pp. 3583-3597
Open Access | Times Cited: 38
An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers
Latifa Zekri, Martina S. Lutz, Nisha Prakash, et al.
Molecular Therapy (2023) Vol. 31, Iss. 4, pp. 1033-1045
Open Access | Times Cited: 24
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
Tanya B. Dorff, Lisa G. Horvath, Karen A. Autio, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 8, pp. 1488-1500
Closed Access | Times Cited: 12
YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Hongtao Song, Tong Lü, Donghui Han, et al.
Cancer Research (2024) Vol. 84, Iss. 22, pp. 3728-3742
Open Access | Times Cited: 8
Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors
Gabrielle Leclercq-Cohen, Nathalie Steinhoff, Hélène Haegel, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 36
Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy
Xiaojing Qin, Wenjing Ning, Han Liu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 6, pp. 2361-2377
Open Access | Times Cited: 7
Mechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors
J. Weddell
CPT Pharmacometrics & Systems Pharmacology (2023) Vol. 12, Iss. 11, pp. 1726-1737
Open Access | Times Cited: 15
Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors
Junjun Liu, Jianwei Zhu
International Immunopharmacology (2024) Vol. 138, pp. 112609-112609
Closed Access | Times Cited: 5
Decoupling Individual Host Response and Immune Cell Engager Cytotoxic Potency
Cristina Gonzàlez Gutierrez, Adrien Aimard, Martine Biarnes‐Pelicot, et al.
ACS Nano (2025)
Open Access
Transcriptomic analysis of human Castration-Resistant prostate cancer: insights into novel therapeutic strategies
G. Ramanjaneyulu, Sneha Jaiswal, Anaswara, et al.
Computational Biology and Chemistry (2025), pp. 108459-108459
Closed Access
Population dynamics of immunological synapse formation induced by bispecific T cell engagers predict clinical pharmacodynamics and treatment resistance
Can Liu, Jiawei Zhou, Stephan T. Kudlacek, et al.
eLife (2023) Vol. 12
Open Access | Times Cited: 12
Using protein geometry to optimize cytotoxicity and the cytokine window of a ROR1 specific T cell engager
Xueyuan Zhou, Felix Klaus Geyer, Dominic Happel, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Camelid‐derived Tcell engagers harnessing human γδ T cells as promising antitumor immunotherapeutic agents
Lola Boutin, Clément Barjon, M Chauvet, et al.
European Journal of Immunology (2024) Vol. 54, Iss. 8
Open Access | Times Cited: 4
Activating adaptive immunity by bispecific, T-cell engager antibodies bridging infected and immune-effector cells is a promising novel therapy for chronic hepatitis B
Zhe Xie, Ulrike Protzer
Antiviral Research (2024) Vol. 229, pp. 105972-105972
Open Access | Times Cited: 4
Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation
Oana Hangiu, Rocío Navarro, Susana Frago, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Unveiling the potential of CLL-1: a promising target for AML therapy
Hamed Soleimani Samarkhazan, Sara Zehtabcheh, Hamideh Rahmani Seraji, et al.
Biomarker Research (2025) Vol. 13, Iss. 1
Open Access
Immunotherapy in Advanced Prostate Cancer—Light at the End of the Tunnel?
Gunhild von Amsberg, Winfried Alsdorf, Panagiotis Karagiannis, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 5, pp. 2569-2569
Open Access | Times Cited: 18
Optimizing Clinical Translation of Bispecific T‐cell Engagers through Context Unification with a Quantitative Systems Pharmacology Model
Xiaozhi Liao, Timothy Qi, Jiawei Zhou, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 2, pp. 415-425
Closed Access | Times Cited: 3
Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release
Eunhee Lee, Shinai Lee, Sumyeong Park, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 10, pp. e007494-e007494
Open Access | Times Cited: 8
CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing
Chen‐Yi Liao, Patrick Engelberts, Andreea Ioan‐Facsinay, et al.
Communications Biology (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 2
Targeting CD276 for T cell-based immunotherapy of breast cancer
Ilona Hagelstein, Laura Wessling, Alexander Rochwarger, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 2
The Evolving Applications of Bispecific Antibodies: Reaping the Harvest of Early Sowing and Planting New Seeds
Diego Ellerman
BioDrugs (2024)
Closed Access | Times Cited: 2
Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours
Yuji Sano, Yumiko Azuma, Toshiaki Tsunenari, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 12
Preclinical characterization of a Fab-like CD3/CLDN18.2 XFab® bispecific antibody against solid tumors
Guili Xu, Niliang Qian, Yujie Liu, et al.
Immunobiology (2022) Vol. 227, Iss. 6, pp. 152283-152283
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top